Concert Pharma (CNCE) Reports Q2 EPS of $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CNCE Hot Sheet
Join SI Premium – FREE
Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of $0.16, versus ($0.41) reported last year. Revenue for the quarter came in at $32 million, versus $6.4 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
